Quebec Reveals Details Of Biosimilar Switching Policy
Biosimilars Canada Welcomes Initiative As Other Provinces Pursue Similar Schemes
Executive Summary
Quebec has revealed further details of its biosimilar switching policy which is expected to generate annual savings of CAD100m by 2022. The move has received support from Biosimilars Canada, as other Canadian provinces pursue similar initiatives.